NCT01008345

Effect of Ezetimibe on Oxidized Low-density Lipoprotein (LDL) Cholesterol

Effect of Ezetimibe on Oxidized LDL Cholesterol

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 100 (actual)
• Sponsor: Hotel Dieu de France Hospital · Academic / Other
• Sex: All
• Age: 21 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Randomized study. Patients with coronary artery disease equivalent will be randomized to receive atorvastatin 40 mg/day + placebo vs. atorvastatin 40 mg/day + ezetimibe 40 mg/day. Oxidized LDL cholesterol will be measured at baseline and after 8 weeks of treatment. Hypothesis is that ezetimibe will lower oxidized LDL

Conditions

• Coronary Artery Disease
• Diabetes

Interventions

Type	Name	Description
DRUG	ezetimibe	Patients will receive 10 mg/day of ezetimibe for 8 weeks

Timeline

• Start date: 2008-09-01
• Primary completion: 2009-06-01
• Completion: 2009-06-01
• First posted: 2009-11-05
• Last updated: 2009-11-06

Locations

1 site across 1 country: Lebanon